Previous 10 | Next 10 |
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Cinacalcet Tablets, a therapeutic equivalent generic version of Sensipar (cinacalcet) Tablets...
Dr. Reddy’s Laboratories ([[RDY]] -0.5%) has launched Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, a generic version of Pfizer' Precedex.Precedex brand and generic market had U.S. sales of ~$210M MAT for the most recent twelve months ending in June 2020 accordi...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr.Reddy’s”) today announced the launch of Dimethyl Fumarate Delayed-Release Capsules, a therapeutic equivalent generic version of Tecfid...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, a therapeutic equivalent gen...
Healthcare solutions provider Global Response Aid ((GRA)) and Dr. Reddy's Lab ([[RDY]]) say that the anti-viral drug Avigan demonstrated 'promising' results against COVID-19, from a Phase 3 study conducted in Japan with the sponsorship of FujiFilm Toyama Chemical.Analysis from ...
Global Response Aid and Dr. Reddy's Laboratories (RDY) -0.7% anti-viral drug Avigan produced promising results in a single-blinded, placebo-controlled Phase 3 clinical study conducted in Japan with the sponsorship of FujiFilm Toyama Chemical. Patients who received Avigan recovered f...
Dr. Reddy's Laboratories has reached an agreement with the Russian authorities to conduct clinical trials and distribution of the COVID-19 Sputnik V vaccine in India. The pharmaceutical company is mostly a generics play but also spends a large amount of revenues on R&D. There ...
Bristol-Myers Squibb (NYSE: BMY) is granting Dr. Reddy's Laboratories (NYSE: RDY) a volume-limited license to produce a generic version of its blockbuster multiple myeloma drug, Revlimid, beginning in 2022. Previously, Bristol-Myers filed a patent-infringement lawsuit against Dr. Reddy'...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”), today announced the settlement of their litigation with Celgene, a wholly owned subsidiary of Bristol Myers Squibb (NYSE: BMY), ...
Bristol Myers Squibb (NYSE: BMY ) has settled its patent infringement litigation against Dr. Reddy's Laboratories (NYSE: RDY ) related to the latter's U.S. application seeking approval of a generic version of multiple myeloma med Revlimid (lenalidomide). More news on: Bristol-Myers S...
News, Short Squeeze, Breakout and More Instantly...
Dr. Reddy's Laboratories Ltd Company Name:
RDY Stock Symbol:
NYSE Market:
Dr. Reddy's Laboratories Ltd Website:
2024-07-04 03:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United States Acquisition seen as ideal anchor to continue to build the company’s global consumer healthcare OTC busines...
Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India. The facility is designed to serve customers with pro...